Request for Covid-19 Impact Assessment of this Report
The increase in use of spirulina as a dietary food supplement, owing to its high nutritional content is the major factor that drives the spirulina market. Furthermore, increase in adoption of healthy food in developed countries fuel the market growth of spirulina in food & beverages. The rise in prevalence of cancer, cardiovascular diseases, immune diseases, and other diseases boosts the demand of spirulina.
Furthermore, increase in healthcare expenditure and disposable income among the population is anticipated to increase the market growth. However, limited resource of spirulina as it is extracted from the freshwater sources that are available in very few areas hinders the market growth. Emerging economies such as India, China, Mexico, and Brazil are anticipated to provide new opportunities for the market growth during the forecast period.
The global spirulina market is segmented into type, application, drug formulation, and region. By type, the market is bifurcated into Arthrospira Platensis and Arthrospira Platensis. Based on application, it is categorized into nutraceuticals, cosmetics, food & beverages, agriculture, feed, and others. Based on drug formulation, the spirulina market is categorized into powder, tablet & capsule, liquid, and granule & gelling agent. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report highlights the market dynamics to understand the global spirulina market and capitalize on the prevailing opportunities.
Quantitative analysis of the current market and forecasts would assist stakeholders to design business strategies accordingly.
Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
• By Type
o Arthrospira Platensis
o Arthrospira Maxima
• By Application
o Nutraceuticals
o Food & Beverages
o Cosmetics
o Animal Feed
o Others
• By Drug Formulation
o Powder
o Tablet & Capsule
o Liquid
o Granule & Gelling Agent
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• Spain
• Italy
• UK
• Rest of Europe
o Asia-Pacific
• Australia
• Japan
• India
• China
• Rest of Asia-Pacific
o LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
KEY MARKET PLAYERS
• Cyanotech
• DIC Corporation
• Chr. Hansen Holding A/S
• Dongtai City Spirulina Bio-engineering Co., Ltd.
• Algenol Biofuels Inc
• Prolgae
• Sensient Technologies Corporation
• Parry Neutraceuticals
• Algatec
The other players in the value chain include (profiles not included in the report):
• GNC Holdings, Inc.
• Now Health Group Inc.
• Fuqing King Dnarmsa Spirulina Co.
• Fraken Biochem Co., Ltd.
• Far East Bio-Tec Co. Ltd.
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.1.1. Top impacting factors
2.1.2. Top investment pockets
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Spirulina Market
3.3.1. Low-to-high bargaining power of suppliers
3.3.2. Moderate-to-high threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Low-to-moderate bargaining power of buyers
3.4. Pricing Analysis
3.4.1. Pricing Analysis, By Region, 2018 & 2025
3.5. Value Chain Analysis
3.6. Impact of government regulations on global spirulina market
3.7. Industry Pain point analysis
3.8. Patent Analysis
3.8.1. By Region (2016-2018)
3.8.2. By Applicant
3.9. Case Studies
3.9.1. Case Study 01
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Rise in demand for natural ingredient
3.10.1.2. Promotion of the production of spirulina by government
3.10.1.3. R&D of spirulina as commercial products
3.10.2. Restraints
3.10.2.1. Impact on spirulina production due to climate change
3.10.3. Opportunities
3.10.3.1. Untapped markets in the developing countries
3.10.3.2. Easy to cultivate due to development in cultivation technology
CHAPTER 4: SPIRULINA MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Arthrospira Platensis
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Arthrospira Maxima
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: SPIRULINA MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Nutraceuticals
5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country
5.3. Cosmetics
5.3.1. Key market trends and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country
5.4. Food and Beverages
5.4.1. Key market trends and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country
5.5. Animal Feed
5.5.1. Key market trends and opportunities
5.5.2. Market size and forecast
5.5.3. Market analysis, by country
5.6. Other applications
5.6.1. Key market trends and opportunities
5.6.2. Market size and forecast
5.6.3. Market analysis, by country
CHAPTER 6: SPIRULINA MARKET, BY DRUG FORMULATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Powder
6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast
6.2.3. Market analysis, by country
6.3. Tablet & Capsule
6.3.1. Key market trends and opportunities
6.3.2. Market size and forecast
6.3.3. Market analysis, by country
6.4. Liquid
6.4.1. Key market trends and opportunities
6.4.2. Market size and forecast
6.4.3. Market analysis, by country
6.5. Granule & Gelling Agent
6.5.1. Key market trends and opportunities
6.5.2. Market size and forecast
6.5.3. Market analysis, by country
CHAPTER 7: SPIRULINA MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by type
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by drug formulation
7.2.5. North America market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by type
7.2.5.2. U.S. market size and forecast, by application
7.2.5.3. U.S. market size and forecast, by drug formulation
7.2.5.4. Canada market size and forecast, by type
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by drug formulation
7.2.5.7. Mexico market size and forecast, by type
7.2.5.8. Mexico market size and forecast, by application
7.2.5.9. Mexico market size and forecast, by drug formulation
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by type
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by drug formulation
7.3.5. Europe market size and forecast, by country
7.3.5.1. France market size and forecast, by type
7.3.5.2. France market size and forecast, by application
7.3.5.3. France market size and forecast, by drug formulation
7.3.5.4. UK market size and forecast, by type
7.3.5.5. UK market size and forecast, by application
7.3.5.6. UK market size and forecast, by drug formulation
7.3.5.7. Italy market size and forecast, by type
7.3.5.8. Italy market size and forecast, by application
7.3.5.9. Italy market size and forecast, by drug formulation
7.3.5.10. Spain market size and forecast, by type
7.3.5.11. Spain market size and forecast, by application
7.3.5.12. Spain market size and forecast, by drug formulation
7.3.5.13. Rest of Europe market size and forecast, by type
7.3.5.14. Rest of Europe market size and forecast, by application
7.3.5.15. Rest of Europe market size and forecast, by drug formulation
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by type
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by drug formulation
7.4.5. Asia-Pacific market size and forecast, by country
7.4.5.1. Japan market size and forecast, by type
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by drug formulation
7.4.5.4. China market size and forecast, by type
7.4.5.5. China market size and forecast, by application
7.4.5.6. China market size and forecast, by drug formulation
7.4.5.7. India market size and forecast, by type
7.4.5.8. India market size and forecast, by application
7.4.5.9. India market size and forecast, by drug formulation
7.4.5.10. Australia market size and forecast, by type
7.4.5.11. Australia market size and forecast, by application
7.4.5.12. Australia market size and forecast, by drug formulation
7.4.5.13. South Korea market size and forecast, by type
7.4.5.14. South Korea market size and forecast, by application
7.4.5.15. South Korea market size and forecast, by drug formulation
7.4.5.16. Rest of Asia-Pacific market size and forecast, by type
7.4.5.17. Rest of Asia-Pacific market size and forecast, by application
7.4.5.18. Rest of Asia-Pacific market size and forecast, by drug formulation
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by type
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by drug formulation
7.5.5. LAMEA market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by type
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by drug formulation
7.5.5.4. South Africa market size and forecast, by type
7.5.5.5. South Africa market size and forecast, by application
7.5.5.6. South Africa market size and forecast, by drug formulation
7.5.5.7. Rest of LAMEA market size and forecast, by type
7.5.5.8. Rest of LAMEA market size and forecast, by application
7.5.5.9. Rest of LAMEA market size and forecast, by drug formulation
CHAPTER 8: COMPANY PROFILES
8.1. Algenol Biofuels Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.2. Dongtai City Spirulina Bio-engineering Co, Ltd.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. CHR. HANSEN HOLDING A/S
8.3.1. Company overview
8.3.2. CHR. Hansen: company Snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. CYANOTECH CORPORATION
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. DDW Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. DIC CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. DÖHLER GMBH
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. FMC CORPORATION
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Givaudan International SA
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. KONINKLIJKE DSM N.V.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Key strategic moves and developments
8.11. Prolgae
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Business performance
8.12. SENSIENT TECHNOLOGIES CORPORATION
8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Product portfolio
8.12.5. Business performance
8.13. E.I.D. Parry Limited
8.13.1. Company overview
8.13.2. Company snapshot
8.13.3. Operating business segments
8.13.4. Product portfolio
8.13.5. Business performance
TABLE 01. GLOBAL SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 02. SPIRULINA MARKET FOR ARTHROSPIRA PLATENSIS, BY REGION, 2018–2026 ($MILLION)
TABLE 03. SPIRULINA MARKET FOR ARTHROSPIRA MAXIMA, BY REGION, 2018–2026 ($MILLION)
TABLE 04. GLOBAL SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 05. SPIRULINA MARKET FOR NUTRACEUTICALS, BY REGION, 2018–2026 ($MILLION)
TABLE 06. SPIRULINA MARKET FOR COSMETICS, BY REGION, 2018–2026 ($MILLION)
TABLE 07. SPIRULINA MARKET FOR FOOD AND BEVERAGES, BY REGION, 2018–2026 ($MILLION)
TABLE 08. SPIRULINA MARKET FOR ANIMAL FEED, BY REGION, 2018–2026 ($MILLION)
TABLE 09. SPIRULINA MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2026 ($MILLION)
TABLE 10. GLOBAL SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 11. SPIRULINA MARKET FOR POWDER, BY REGION, 2018–2026 ($MILLION)
TABLE 12. SPIRULINA MARKET FOR TABLET & CAPSULE, BY REGION, 2018–2026 ($MILLION)
TABLE 13. SPIRULINA MARKET FOR LIQUID, BY REGION, 2018–2026 ($MILLION)
TABLE 14. SPIRULINA MARKET FOR GRANULE & GELLING AGENT, BY REGION, 2018–2026 ($MILLION)
TABLE 15. GLOBAL SPIRULINA MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 18. NORTH AMERICA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 19. NORTH AMERICA SPIRULINA MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20. U.S. SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 21. U.S. SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 22. U.S. SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 23. CANADA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 24. CANADA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 25. CANADA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 26. MEXICO SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 27. MEXICO SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 28. MEXICO SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 29. EUROPE SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 30. EUROPE SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 31. EUROPE SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 32. EUROPE SPIRULINA MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 33. FRANCE SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 34. FRANCE SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 35. FRANCE SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 36. UK SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 37. UK SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 38. UK SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 39. ITALY SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 40. ITALY SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. ITALY SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 42. SPAIN SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 43. SPAIN SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 44. SPAIN SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 45. REST OF EUROPE SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 46. REST OF EUROPE SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 47. REST OF EUROPE SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 48. ASIA-PACIFIC SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 49. ASIA-PACIFIC SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 50. ASIA-PACIFIC SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 51. ASIA-PACIFIC SPIRULINA MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. JAPAN SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 53. JAPAN SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 54. JAPAN SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 55. CHINA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 56. CHINA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 57. CHINA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 58. INDIA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 59. INDIA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 60. INDIA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 61. AUSTRALIA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 62. AUSTRALIA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 63. AUSTRALIA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 64. SOUTH KOREA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 65. SOUTH KOREA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 66. SOUTH KOREA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 70. LAMEA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 71. LAMEA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 72. LAMEA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 73. LAMEA SPIRULINA MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 74. BRAZIL SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 75. BRAZIL SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 76. BRAZIL SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 77. SOUTH AFRICA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 78. SOUTH AFRICA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 79. SOUTH AFRICA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 80. REST OF LAMEA SPIRULINA MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 81. REST OF LAMEA SPIRULINA MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 82. REST OF LAMEA SPIRULINA MARKET, BY DRUG FORMULATION, 2018–2026 ($MILLION)
TABLE 83. ALGENOL: COMPANY SNAPSHOT
TABLE 84. ALGENOL: OPERATING SEGMENTS
TABLE 85. ALGENOL: PRODUCT PORTFOLIO
TABLE 86. DONGTAI: COMPANY SNAPSHOT
TABLE 87. DONGTAI: OPERATING SEGMENTS
TABLE 88. DONGTAI: PRODUCT PORTFOLIO
TABLE 89. CHR. HANSEN: OPERATING SEGMENTS
TABLE 90. CHR HANSEN: PRODUCT PORTFOLIO
TABLE 91. CYANOTECH: COMPANY SNAPSHOT
TABLE 92. CYANOTECH: OPERATING SEGMENTS
TABLE 93. CYANOTECH: PRODUCT PORTFOLIO
TABLE 94. DDW INC: COMPANY SNAPSHOT
TABLE 95. DDW INC: OPERATING SEGMENTS:
TABLE 96. DDW INC: PRODUCT PORTFOLIO
TABLE 97. DIC: COMPANY SNAPSHOT
TABLE 98. DIC: OPERATING SEGMENTS
TABLE 99. DIC: PRODUCT PORTFOLIO
TABLE 100. DÖHLER: COMPANY SNAPSHOT
TABLE 101. DÖHLER: OPERATING SEGMENTS
TABLE 102. DÖHLER: PRODUCT PORTFOLIO
TABLE 103. SANOFI: COMPANY SNAPSHOT
TABLE 104. SANOFI: OPERATING SEGMENTS
TABLE 105. SANOFI: PRODUCT PORTFOLIO
TABLE 106. GIVAUDAN: COMPANY SNAPSHOT
TABLE 107. GIVAUDAN: OPERATING SEGMENTS
TABLE 108. GIVAUDAN: PRODUCT PORTFOLIO
TABLE 109. VAXXINOVA: COMPANY SNAPSHOT
TABLE 110. VAXXINOVA: OPERATING SEGMENTS
TABLE 111. VAXXINOVA: PRODUCT PORTFOLIO
TABLE 112. NATUREX: COMPANY SNAPSHOT
TABLE 113. NATUREX: OPERATING SEGMENTS
TABLE 114. NATUREX: PRODUCT PORTFOLIO
TABLE 115. SENSIENT: COMPANY SNAPSHOT
TABLE 116. SENSIENT: OPERATING SEGMENTS
TABLE 117. SENSIENT: PRODUCT PORTFOLIO
TABLE 118. PARRY: COMPANY SNAPSHOT
TABLE 119. PARRY: OPERATING SEGMENTS
TABLE 120. PARRY: PRODUCT PORTFOLIO
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...